Assertio (ASRT) Competitors $0.86 0.00 (-0.27%) Closing price 04:00 PM EasternExtended Trading$0.87 +0.01 (+0.63%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. AARD, CGEM, DSGN, ALT, ALDX, LYEL, RCKT, LBRX, CAPR, and ALECShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Aardvark Therapeutics (AARD), Cullinan Therapeutics (CGEM), Design Therapeutics (DSGN), Altimmune (ALT), Aldeyra Therapeutics (ALDX), Lyell Immunopharma (LYEL), Rocket Pharmaceuticals (RCKT), LB Pharmaceuticals (LBRX), Capricor Therapeutics (CAPR), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Its Competitors Aardvark Therapeutics Cullinan Therapeutics Design Therapeutics Altimmune Aldeyra Therapeutics Lyell Immunopharma Rocket Pharmaceuticals LB Pharmaceuticals Capricor Therapeutics Alector Aardvark Therapeutics (NASDAQ:AARD) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Do insiders and institutionals hold more shares of AARD or ASRT? 49.0% of Assertio shares are owned by institutional investors. 4.0% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is AARD or ASRT more profitable? Aardvark Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -36.97%. Aardvark Therapeutics' return on equity of 0.00% beat Assertio's return on equity.Company Net Margins Return on Equity Return on Assets Aardvark TherapeuticsN/A N/A N/A Assertio -36.97%-38.19%-15.45% Do analysts prefer AARD or ASRT? Aardvark Therapeutics presently has a consensus price target of $31.43, suggesting a potential upside of 125.62%. Assertio has a consensus price target of $2.38, suggesting a potential upside of 175.97%. Given Assertio's higher probable upside, analysts plainly believe Assertio is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Assertio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has preferable earnings and valuation, AARD or ASRT? Aardvark Therapeutics has higher earnings, but lower revenue than Assertio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAardvark TherapeuticsN/AN/A-$20.59MN/AN/AAssertio$124.96M0.66-$21.58M-$0.45-1.91 Does the media favor AARD or ASRT? In the previous week, Assertio had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 4 mentions for Assertio and 3 mentions for Aardvark Therapeutics. Assertio's average media sentiment score of 0.83 beat Aardvark Therapeutics' score of 0.61 indicating that Assertio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAardvark Therapeutics and Assertio tied by winning 6 of the 12 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.82M$2.62B$6.05B$10.51BDividend YieldN/A57.77%5.73%4.80%P/E Ratio-1.9122.7985.4427.36Price / Sales0.66557.61515.26195.91Price / Cash17.15174.0137.5761.53Price / Book0.685.5112.426.82Net Income-$21.58M$33.06M$3.32B$276.89M7 Day Performance-3.09%0.95%1.01%0.27%1 Month Performance7.16%14.25%10.75%8.31%1 Year Performance-23.84%0.85%76.20%35.60% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio2.8777 of 5 stars$0.86-0.3%$2.38+176.0%-23.0%$82.82M$124.96M-1.9120Analyst UpgradeAARDAardvark Therapeutics4.4694 of 5 stars$17.05+6.0%$31.43+84.3%N/A$348.89MN/A0.0018Gap UpCGEMCullinan Therapeutics3.3176 of 5 stars$5.84-1.0%$26.00+345.2%-52.3%$348.54MN/A-1.8130News CoveragePositive NewsDSGNDesign Therapeutics0.2822 of 5 stars$6.35+3.9%N/A+28.5%$347.95MN/A-5.6740ALTAltimmune2.8777 of 5 stars$4.01+2.6%$17.40+333.9%-38.3%$345.09M$20K-3.4050ALDXAldeyra Therapeutics1.8144 of 5 stars$5.51-4.0%$9.50+72.4%-1.8%$343.80MN/A-6.4810LYELLyell Immunopharma1.4766 of 5 stars$17.85+0.6%$15.00-16.0%-29.2%$341M$60K-0.73270Positive NewsRCKTRocket Pharmaceuticals4.7701 of 5 stars$3.18+1.0%$16.67+424.1%-74.7%$339.90MN/A-1.27240News CoverageAnalyst ForecastLBRXLB PharmaceuticalsN/A$15.14+0.6%$30.50+101.5%N/A$337.77MN/A0.0016News CoveragePositive NewsCAPRCapricor Therapeutics1.9312 of 5 stars$7.81+6.1%$22.25+184.9%-65.8%$336.48M$22.27M-4.76101ALECAlector3.5217 of 5 stars$3.18-4.2%$4.17+31.0%-39.0%$336.02M$100.56M-2.74270 Related Companies and Tools Related Companies Aardvark Therapeutics Competitors Cullinan Therapeutics Competitors Design Therapeutics Competitors Altimmune Competitors Aldeyra Therapeutics Competitors Lyell Immunopharma Competitors Rocket Pharmaceuticals Competitors LB Pharmaceuticals Competitors Capricor Therapeutics Competitors Alector Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
